Novartis
-
Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review
Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.
-
Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders
Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Novartis cancer drug is now first approved therapy for group of rare, genetic diseases
A Novartis drug that stops abnormal cell growth in breast cancer now has an additional FDA approval treating a group of rare disorders characterized by overgrowth in various types of tissue. The regulatory decision makes the drug, Vijoice, the first approved therapy for these disorders termed “PROS.”
-
Novartis restructures to save $1B; pharma & oncology to merge into single unit
Novartis unveiled a corporate restructuring that is consolidating some operations in cash-saving moves expected to lead to $1 billion in annual savings. The shakeup means the departure of several key executives, including Chief Medical Officer John Tsai, who has held that role since 2018.
-
Novartis targeted radiation therapy gets FDA nod for advanced prostate cancer
The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.
-
Novartis turns to Voyager Therapeutics to get gene therapies into the brain
Novartis is paying Voyager Therapeutics $53 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene therapies. Depending on the progress of the research, Voyager could earn up to $1.5 billion in milestone payments.
-
FDA nod for Novartis sets up cholesterol drug showdown with Amgen, Regeneron
Novartis drug Leqvio now has the FDA’s green light, making it the first RNA interference medicine approved for lowering cholesterol. The regulatory decision sets the stage for competition against cholesterol medicines from Amgen and Regeneron that also address liver protein PCSK9.
-
Novartis commits $1.5B to acquire eye disease gene therapy biotech Gyroscope
Novartis is acquiring gene therapy developer Gyroscope Therapeutics and its lead program, a potential treatment for the vision loss disorder geographic atrophy. It’s the latest in a series of M&A moves made by Novartis to build up its gene therapy pipeline.
-
Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene’s antibody drug.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the progress of those drugs, UCB could earn up to $1.5 billion in milestone payments.
-
Novartis is cashing out of Roche for $21B, 20 years after mega-merger that never happened
Novartis’s equity stake in Roche, shares acquired 20 years ago in a strategy to build up to a potential mega-merger, will be sold back to the company in a $20.7 billion deal. The cash proceeds could fuel Novartis R&D, as well as potential dealmaking.
-
Novartis “one transplant for life” drug flunks test in kidney transplant patients
A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney transplant patients. Other clinical trial failures announced ahead of the Labor Day weekend include a Forte Biosciences atopic dermatitis drug, as well a cancer therapy from Takeda Pharmaceutical.
-
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity
Novartis was unsuccessful developing bimagrumab as a treatment for a rare muscle disorder, but additional tests showed encouraging results in fat reduction. Startup Versanis Bio licensed rights to the antibody and plans to use its Series A financing for clinical trials testing the drug in obese patients.
-
Novartis radiopharmaceutical improves survival in key prostate cancer study
Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.
-
EMD Serono targeted therapy gets speedy FDA approval for lung cancer
EMD Serono’s Tepmetko is one of a number of targeted cancer therapies that have passed FDA muster in the past year. The decision sets up the German company’s pill for head-to-head competition with a Novartis drug targeting the same genetic signature.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
